ArticleScientific reports2025
The study of miR-130a expression and its mechanism of action in peripheral blood endothelial progenitor cells (EPCs) in type 2 diabetes mellitus (T2DM).
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Cardiovascular Dysfunction in Type 2 Diabetes: The Role of MicroRNAs.Handbook of experimental pharmacology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
TGF-β1 has been reported to suppress miR-130a expression, while being elevated in patients with type 2 diabetes mellitus (T2DM). And IL-18, a potential target of miR-130a, is also up-regulated in T2DM patients. In this study, we aim to investigate the potential involvement of the TGFβ1/miR-130a/IL-18 axis underlying the dysfunction of endothelial progenitor cells (EPCs) in T2DM patients. We performed luciferase assays to confirm the molecular binding between miR-130a, TGF-β1 and IL-18, and real-time PCR and ELISA were performed to observe the changes of TGF-β1, miR-130a, IL-18 and IFN-γ in different cell groups. Tube formation assay, cell adhesion assay and Transwell assay were performed to evaluate effect of TGF-β1/miR-130a/IL-18 axis on the EPCs functions. Accordingly, in EPCs treated with TGF-β1, we found that the levels of miR-130a were reduced, and its expressions were also negatively correlated with the expressions of IL-18 in the EPC groups. Luciferase assays validated IL-18 as a target gene of miR-130a. The over-expression of IL-18, as well as the knockdown of miR-130a, not only increased the expressions of TGF-β1 in EPCs, but also promoted the tube formation, adhesion and migration of EPCs. By contrast, the knockdown of IL-18, as well as the over-regulation of miR-130a, exhibited suppressive effect on the levels of TGF-β1, while inhibiting the tube formation, adhesion and migration of EPCs. In this study, we elucidated the impact of the TGFβ1/miR-130a/IL-18 signaling pathway on the function of EPCs, thus providing theoretical basis for the development of miRNA-targeted therapeutic strategies for patients withT2DM and associated complications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.